When Wegovy Stops Working: Is Wegovy HD Right for You?
You’ve been on Wegovy for months. The first 20, 30, maybe 40 pounds came off. And then — nothing. The scale hasn’t moved in weeks. You’re doing everything right, but the medication that was working before seems to have hit a wall.
This is the plateau. It’s not a failure. It’s a normal part of GLP-1 therapy — and it has a clinical name: tachyphylaxis. When it happens, the question isn’t whether to keep going, it’s whether to adjust the dose. That’s where Wegovy HD (7.2 mg) comes in.
Wegovy HD is the new highest-dose formulation of semaglutide, approved by the FDA on March 19, 2026. It delivers 7.2 mg of semaglutide weekly — three times the standard maximum dose of 2.4 mg — and is specifically designed for patients who have tolerated 2.4 mg and need additional weight reduction. Clinical Nutrition Center in Greenwood Village is now assessing and prescribing Wegovy HD for eligible patients.
What Is Wegovy HD?
Wegovy HD (semaglutide injection 7.2 mg) is a higher-dose formulation of the GLP-1 receptor agonist Wegovy Approved by the FDA on March 19, 2026, it is indicated as an adjunct to a reduced-calorie diet and increased physical activity for:
- Weight loss in adults with obesity (BMI ≥ 30 kg/m²) or overweight with at least one weight-related comorbidity
- Maintenance of weight loss and long-term weight management
To start Wegovy HD, you must have tolerated the 2.4 mg dose for at least 4 weeks. The 7.2 mg dose is administered as a once-weekly subcutaneous injection via a single-dose pen. Wegovy HD is not a starting dose — it’s the next clinical step for appropriate patients.
It is not the same as increasing your dose arbitrarily. Your CNC provider will assess whether you are clinically appropriate for the escalation based on your response, tolerance, and weight trajectory.
What the Clinical Data Shows: STEP UP Trial Results
FDA approval of Wegovy HD was based on the STEP UP trial — a 72-week randomized controlled trial in 1,407 adults with obesity (BMI ≥ 30 kg/m²) without type 2 diabetes. The study compared once-weekly semaglutide 7.2 mg to placebo and to semaglutide 2.4 mg.
| Wegovy 7.2 mg | Wegovy 2.4 mg | Placebo | |
|---|---|---|---|
| Mean weight loss (efficacy estimand*) |
~21% (20.7%) | ~18% (17.5%) | ~2% (2.4%) |
| Mean weight loss (treatment regimen estimand**) |
~19% (18.8%) | ~16% (15.5%) | ~4% (3.9%) |
| Patients achieving ≥25% weight loss | 31.2% | 15.3% | 0% |
*Efficacy estimand = all patients who stayed on treatment for 72 weeks
**Treatment regimen estimand = all patients regardless of whether they stayed on treatment
The average trial participant on 7.2 mg started at approximately 248 lb and lost roughly 52 lb at 72 weeks on the efficacy estimand. More importantly for plateau patients: 31% of patients on 7.2 mg achieved 25% or greater total body weight loss — compared to 15% on 2.4 mg and essentially zero on placebo.
If you’ve been stalled at 15–17% weight loss on 2.4 mg, the STEP UP data suggests there’s meaningful room to go further on 7.2 mg.
What the Dose Increase Actually Looks Like
Escalating from 2.4 mg to 7.2 mg is not a single jump — it happens gradually, as with all Wegovy dose increases. You will typically step up through intermediate doses (3.0 mg, 4.5 mg) over several weeks, giving your body time to adjust at each level.
Your CNC provider will guide the escalation schedule based on how you’ve tolerated prior increases. The goal is to reach the highest tolerated dose — not to rush to 7.2 mg. Some patients tolerate the transition well; others need more time at intermediate doses.
The key difference from 2.4 mg: at 7.2 mg, the most common new side effect is dysesthesia — a sensation of tingling, numbness, or burning on the skin. In clinical trials, 22% of patients on 7.2 mg reported this, compared to 6% on 2.4 mg and 0.3% on placebo. It’s not dangerous, but it can be bothersome enough that some patients discontinue. Your CNC provider will discuss whether this risk is acceptable for your situation before escalating.
How Wegovy HD Compares to Switching to Zepbound
If you’ve plateaued on Wegovy, you’ve probably seen information about Zepbound (tirzepatide). Zepbound activates both the GLP-1 and the GIP hormone pathways — which can produce greater average weight loss in some patients. The average weight loss numbers for Zepbound (SURMOUNT trials) are comparable to Wegovy HD.
The choice between escalating to Wegovy HD vs. switching to Zepbound is a clinical decision. The main considerations:
- Wegovy HD stays within the semaglutide class — appropriate if you’re tolerating Wegovy well and just need more signal
- Switching to Zepbound means starting over with dose escalation from 2.5 mg — which can mean weeks before you reach a therapeutic dose equivalent
- If you’ve had gastrointestinal side effects on Wegovy, you may experience similar effects on Zepbound
- Zepbound is a dual GLP-1/GIP agonist with a different mechanism — some patients who don’t respond well to semaglutide alone respond better to dual agonism
See our full Wegovy vs. Zepbound comparison →
Your CNC provider will review your history, tolerance, weight trajectory, and goals to determine which escalation or switch is right for you. Book a plateau consultation →
Medicare Bridge Coverage: How Much Does Wegovy HD Cost?
Wegovy HD is the same active ingredient (semaglutide) as regular Wegovy, just at a higher dose. Under the 2026 Medicare GLP-1 Bridge program, Wegovy HD is covered at the same $50/month copay as other Wegovy doses for the weight loss indication. If you are on Medicare Part D, you may qualify.
- Medicare Part D (Bridge): $50/month for eligible beneficiaries — covers Wegovy HD for weight loss indication
- Commercial insurance: Coverage varies by plan. CNC handles prior authorizations on your behalf.
- Self-pay: CNC offers transparent self-pay pricing. Ask at your consultation.
CNC is a direct-pay clinic. We do not bill insurance directly, but we provide all documentation for out-of-network reimbursement and submit prior authorizations for Medicare and most commercial plans.
Hitting a Plateau Isn’t the End — It’s a Clinical Decision Point
If you’ve been on Wegovy 2.4 mg and the scale has stopped moving, that’s information — not a verdict. The clinical question is whether a dose adjustment, a medication switch, or a plan change is right for you. Book a consultation at our Greenwood Village clinic and let’s find out.
Frequently Asked Questions
I’ve been on Wegovy 2.4 mg for months and I’ve stopped losing weight. Does this mean it’s stopped working?
Not exactly. Tachyphylaxis — reduced response over time — is a recognized part of GLP-1 therapy. It doesn’t mean the medication has stopped working entirely; it means your body has adapted to the current dose. For some patients, the solution is dose escalation to 7.2 mg. For others, switching to a different medication class (such as Zepbound/tirzepatide) may produce a stronger response. Your CNC provider will assess your specific situation.
How is Wegovy HD different from just increasing my dose on my own?
You cannot simply take more Wegovy on your own. Wegovy HD is a distinct formulation at 7.2 mg — three times the standard 2.4 mg dose — and is only available at that specific dose strength. Dose escalation must be clinically assessed and managed by a physician. At CNC, your provider will confirm you are tolerating 2.4 mg well, review your weight trajectory, and determine whether escalation to 7.2 mg is appropriate.
What’s the biggest risk of going from 2.4 mg to 7.2 mg?
Dysesthesia — a sensation of tingling, numbness, or burning on the skin — occurred in 22% of patients on 7.2 mg in the STEP UP trial, compared to 6% on 2.4 mg and less than 1% on placebo. This side effect is not dangerous, but it was the most common reason patients discontinued Wegovy HD in clinical trials. Your CNC provider will discuss this risk with you before escalating.
Can I switch from Wegovy 2.4 mg directly to Zepbound instead of going to 7.2 mg?
Yes — switching from Wegovy to Zepbound is a clinical option. Zepbound (tirzepatide) is a dual GLP-1/GIP agonist with comparable average weight loss to Wegovy HD. The main trade-off is that switching means starting over at the lowest Zepbound dose (2.5 mg) and escalating from there, which takes several weeks before reaching a therapeutic equivalent. Some patients prefer to try the Wegovy HD step-up first; others prefer the dual agonism approach. Your CNC provider will help you decide.
Is Wegovy HD covered by Medicare?
Yes. Under the 2026 Medicare GLP-1 Bridge program, Wegovy HD is covered at the same $50/month copay as other Wegovy doses for the weight loss indication. See full Bridge coverage details →
How long does the dose escalation to 7.2 mg take?
You won’t go directly from 2.4 mg to 7.2 mg. Wegovy dose escalation follows a stepped schedule, typically moving through intermediate doses (3.0 mg, 4.5 mg) over several weeks. Most patients reach 7.2 mg within 8–12 weeks of starting the escalation process, depending on tolerance at each step. Your CNC provider will individualize the schedule.
Reviewed by Ethan Lazarus, MD, MFOMA — Clinical Nutrition Center, 5995 Greenwood Plaza Blvd, Suite 150, Greenwood Village, CO 80111 · (303) 750-9454. Last reviewed July 2026.